<DOC>
	<DOCNO>NCT01188343</DOCNO>
	<brief_summary>This study design compare immunogenicity Japanese encephalitis chimeric virus vaccine ( JE-CV ) measles-mumps-rubella ( MMR ) vaccine give together give separate visit 6 week apart toddler age 12 18 month . Primary objective : - To demonstrate non-inferiority antibody responses term seroconversion concomitant administration JE-CV MMR compare antibody responses single administration JE-CV MMR vaccine . Secondary objective : - To describe immune response JE CV MMR one dose JE CV MMR vaccine , respectively . - To describe safety single dose JE-CV MMR vaccine ( give separately 6-week interval safety concomitant administration JE-CV MMR vaccine subject 6 month last vaccination .</brief_summary>
	<brief_title>Study Japanese Encephalitis Chimeric Virus Vaccine Given With Measles-Mumps-Rubella Vaccine Taiwanese Toddlers</brief_title>
	<detailed_description>All participant receive Japanese encephalitis chimeric virus vaccine measles-mumps-rubella vaccine monitor safety throughout study .</detailed_description>
	<mesh_term>Encephalitis</mesh_term>
	<mesh_term>Measles</mesh_term>
	<mesh_term>Rubella</mesh_term>
	<mesh_term>Encephalitis , Japanese</mesh_term>
	<mesh_term>Mumps</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion Criteria Aged 12 18 month day inclusion . Born full term pregnancy ( ≥ 37 week ) birth weight ≥ 2.5 kg . Subject good health base medical history physical examination . Provision informed consent form sign least one parent legally acceptable representative , independent witness parent legally acceptable representative read . Subject parent/legally acceptable representative delegate able attend schedule visit comply trial procedure . Exclusion Criteria Participation another clinical trial investigate vaccine , drug , medical device , medical procedure 4 week precede first trial vaccination . Planned participation another clinical trial present trial period . Receipt vaccine 4 week precede first trial vaccination except pandemic influenza vaccination , may receive least two week study vaccine . Planned receipt vaccine 6 week follow last trial vaccination except pandemic influenza vaccine . In event local national immunization program pandemic influenza vaccine , participant receive pandemic influenza vaccine time trial withdrawn trial . Previous vaccination measles , measlesmumpsrubella ( MMR ) , flavivirus disease , include Japanese encephalitis ( JE ) . Receipt blood past 6 month might interfere assessment immune response Receipt intravenous injection plasma , platelet product , high dose intravenous immunoglobulin past 11 month Receipt intramuscular treatment immunoglobulin Hepatitis B immunoglobulin past 3 month Known suspected congenital acquire immunodeficiency , immunosuppressive therapy anticancer chemotherapy radiation therapy within precede 6 month , longterm systemic corticosteroid therapy . Known history human immunodeficiency virus , hepatitis B surface antigen , hepatitis C seropositivity . History measles , mumps , rubella , flavivirus infection confirm either clinically , serologically , microbiologically . Known systemic hypersensitivity vaccine component history lifethreatening reaction vaccine contain substance . Known systemic hypersensitivity gelatin , egg , anaphylactic/anaphylactoid reaction neomycin . Known history thrombocytopenia . Administration antiviral within 2 month precede first vaccination 6 week follow last trial vaccination . History central nervous system disorder disease , include seizure febrile seizure . Chronic illness stage could interfere trial conduct completion , opinion Investigator .</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>18 Months</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Japanese Encephalitis</keyword>
	<keyword>Japanese encephalitis chimeric virus vaccine</keyword>
	<keyword>Measles</keyword>
	<keyword>Mumps</keyword>
	<keyword>Rubella</keyword>
</DOC>